LCB-2151 (Compound 2) is a nucleoside analog and an anticancer agent. It disrupts the two main sources of ATP production, glycolysis and mitochondrial oxidative phosphorylation, reducing the bioenergetic capacity of KRAS mutant pancreatic cancer cells and inducing the formation of ROS. LCB-2151 effectively inhibits key enzymes in glycolysis, the TCA cycle, and fatty acid beta-oxidation, such as CACT and CPT2. It demonstrates significant cytotoxicity and can induce apoptosis. LCB-2151 is applicable in cancer radiotherapy research.
